WEBINAR | FINANCIAL VALUATION MODELS FOR LIFE SCIENCE COMPANIES - A MORE DETAILED EXPLANATION OF CONCEPTS


Financial Valuation Models for Life Science Companies – A More Detailed Explanation of Concepts

This webinar is a continuation of the first webinar, entitled "Must-Know Finance Concepts for Life Sciences Valuations," and goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets.

Part 2 discusses:

  • Which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions?

  • An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value

  • What are some cash flow examples for a situation when the asset is early in the product lifecycle, for out-licensed, and for in-licensed products?

  • How do my expected deal terms relate to my forecast cash flows? How can I use this to make better decisions on licensing timing?

  • And more...

If you are an entrepreneur who plans to raise (or currently is raising) financing, licensing and asset, or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the life sciences investing sector, you'll benefit from this more detailed explanation of life sciences valuation methodologies.



WATCH THE 
WEBINAR


ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives organizations of all sizes in all industries the confidence to simply and securely share sensitive documents with third parties during due diligence, fundraising, board communications, and any circumstance when it is crucial that confidential information is maintained under the highest level of security and control.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.

MODERATOR AND PANELISTS:

Company team

John Selig

Co-Founder and Managing Partner of Mavericks Capital

John advises life sciences companies on M&A, licensing and financial strategy. He teaches the valuation and finance module at BIO’s Executive Management course for BD professionals and at Stanford Medical School’s Entrepreneurship program. Learn More

Company team

Jeff Karan

Co-Founder and Managing Partner of Mavericks Capital

Jeff brings over 30 years of investment banking and corporate advisory experience to Mavericks Capital.  In addition to his extensive knowledge of capital raising and merger & acquisitions, Jeff has advised clients on corporate strategy, business valuation, and a wide range of strategic partnership structures. Learn More